Lupin Limited
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, founded in 1968. It specializes in the development, manufacturing, and commercialization of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and advanced drug delivery systems. Lupin offers a broad portfolio of pharmaceutical products that treat a wide range of therapeutic areas including tuberculosis, diabetes, asthma, cardiovascular diseases, infections, pain management, analgesics, gastrointestinal care, respiratory, dermatology, and multivitamins. Its product brands include diabetes care medicines such as Gibtulio, Ajaduo, Gibtulio Met, ONDERO, and ONDERO MET, as well as a Huminsulin range including Insulin Human. Lupin operates in over 100 countries, with significant market presence in India, the United States, South Africa, Asia Pacific, Latin America, Europe, and the Middle East. The company has production facilities in India, the US, Mexico, and Brazil and employs over 19,000 people globally. In the last two years, Lupin has undergone significant strategic transformations including the formal carving out of its trade generics business into a wholly owned subsidiary, Lupin Life Sciences, in July 2024 to enhance operational focus and agility. Lupin Manufacturing Solutions (LMS) has conceptualized a multi-year growth strategy to position itself as a differentiated CDMO partner offering end-to-end solutions for global pharma innovators. The company has expanded its portfolio to include approximately 350 products under Lupin Life Sciences, emphasizing high-quality, accessible medicines across multiple therapeutic categories. In 2024, Lupin completed strategic acquisitions of brands from Sanofi in Europe and Canada and several brands of the Medical Nutritional Institute, bolstering its respiratory business and geographic footprint. Lupin has also received U.S. FDA approval for its biosimilar Armlupeg™ (Pegfilgrastim-unne), further advancing its biopharma capabilities. The company continues to invest in expanding manufacturing infrastructure with plans for new facilities announced in 2025 aimed at enhancing capacity and global supply chain security. Lupin’s integrated approach spans from active pharmaceutical ingredient production through branded and generic formulations, with a focus on innovation, regulatory compliance, and global market diversification. The company targets diverse customer segments including healthcare providers, pharmaceutical companies, and end consumers in both developed and emerging markets. Its ongoing strategic shifts, acquisitions, and regulatory achievements underscore Lupin’s commitment to growth and leadership in the global pharmaceutical industry.
Company News
Lupin et Tenpoint Therapeutics annoncent un partenariat stratégique visant à commercialiser YUVEZZI™ dans l'Union européenne, au Royaume-Uni, en Suisse, en Norvège et en Islande
Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
Lupin Announces the Approval of Diazepam Injection, USP in the United States
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
Lupin Launches Azilsartan Medoxomil Tablets in the United States
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
Lupin erhält Zulassung in China für Oseltamivirphosphat-Suspension zum Einnehmen
Lupin reçoit l'approbation de la Chine pour la suspension orale de phosphate d'oseltamivir
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
Lupin Launches Dapagliflozin Tablets in the United States
Lupin Completes Acquisition of VISUfarma
Lupin finalise l'acquisition de VISUfarma
Lupin schließt Übernahme von VISUfarma ab
Lupin Completa la Adquisición de VISUfarma